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ABSTRACT
Insulin resistance (IR) is defined by the inability of insulin to exert its metabolic actions, due to
impaired activation of intracellular insulin signaling. This condition is caused by genetic defects or
by environmental conditions, among which the most common is obesity. Systemic  IR determines10 the development of hepatic fat accumulation, which can progress to nonalcoholic steatohepatitis,
cirrhosis and hepatocellular carcinoma, and is a major determinant of liver disease independently
of coexisting factors. Therefore, insulin-sensitizing drugs are currently under evaluation to
improve steatohepatitis. Indeed, manipulation of nuclear hormone receptors is already under
scrutiny for liver disease prevention by amelioration of  IR, whereas NOTCH signaling inhibition15 represents a novel approach. Nevertheless, further research is warranted to better understand the
mechanism linking  IR to progressive fibrogenesis in the absence of inflammation and to identify
novel drug targets.
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Introduction: the insulin resistance – fatty liver
syndromeAQ1
20 Insulin resistance (IR) is traditionally defined as reduced
insulin capability to increase glucose uptake and utiliza-
tion. It is a complex condition in which the liver, skeletal
muscles  and white adipose tissue become less sensitive
to insulin and its downstream metabolic actions under
25 normal serum glucose concentration. However, hepatic
IR is characterized by a dissociation of the effect of
insulin on glucose and lipid metabolism, in that hepatic
de novo lipogenesis is paradoxically increased. The phe-
notypic expression of IR is dependent upon genetic
30 defects or environmental triggering conditions, among
which the most common is obesity. Indeed, obesity
leads to adipose tissue inflammation and adipose IR,
with spillover of lipids and ectopic fat accumulation in
the muscles and visceral organs, determining altera-
35 tions in the intracellular pathways regulating the
response to insulin binding to its receptor. Altered
secretion of adipokines contributes to a proinflamma-
tory state  and in turn increases IR.
A major role in the development of systemic IR
syndrome is played by hepatocellular fat accumulation,
40   i.e. steatosis. In particular, nonalcoholic fatty liver dis-
ease (NAFLD), defined as triglyceride’s (TG) accumula-
tion in excess of 5% of liver weight in the absence of at
risk alcohol drinking, has recently gained attention as a
key player in liver disease progression.[1] Paralleling the
45obesity epidemics, NAFLD has become the leading
cause of liver disease in Western countries.[2] Indeed,
the prevalence of NAFLD increases with body mass
index,[3] reaching 60–70% in obese patients.[4]
Moreover, the risk of developing the progressive form
50of the disease, presently identified as nonalcoholic stea-
tohepatitis (NASH), is higher in obese subjects.
In susceptible individuals NASH may lead to hepatic
complications such as cirrhosis and hepatocellular carci-
noma (HCC), the risk being higher in those with more
55severe IR and type 2 diabetes mellitus (T2DM).
Importantly, NAFLD frequently coexists with other liver
diseases, related, for example, to alcohol abuse and
chronic viral hepatitis, increasing the risk of disease pro-
gression. On the other hand, NAFLD also confers
60increased predisposition to extrahepatic complications
of metabolic syndrome (MetS), including T2DM, pro-
atherogenic dyslipidemia  and cardiovascular disease.
As a key component of MetS, NAFLD is also closely
associated with visceral obesity, and represents the
65hepatic manifestation of MetS. In this context, T2DM is
the consequence of β-cell exhaustion in the setting of
IR, and now a common determinant of liver disease.[5]
Virtually, the entire spectrum of liver disease is seen in
patients with T2DM. This includes abnormal liver
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70 enzymes, NAFLD, cirrhosis, HCC  and acute liver failure.
The prevalence of NAFLD in T2DM patients is estimated
at 34–74% and at 100% in T2DM with obesity.[6] Vice
versa, NAFLD may contribute IR. Aminotransferase
levels, reflecting hepatic fat content in individuals with-
75 out viral hepatitis and alcohol abuse, predict T2DM
development.[7,8] The mechanism may involve altered
release of hepatokines influencing insulin signaling. IR,
NAFLD  and T2DM are all characterized by pro-athero-
genic dyslipidemia, defined by hypertriglyceridemia,
80 low high-density lipoprotein cholesterol concentrations,
and the predominance of small dense LDL.[9]
Finally, hypertension has been associated with IR,
obesity and T2DM. The high prevalence of NAFLD in
non-obese hypertensive patients with normal liver
85 enzymes appears related to increases in IR and body
weight. Importantly, T2DM and hypertension are inde-
pendent risk factors for the progression of liver fibrosis
in NAFLD, possibly via activation of the renin–angioten-
sin–aldosterone axis.[10,11]
90 This review is aimed to summarize the general
aspects of IR, its pathophysiology and the role of IR in
the pathogenesis of chronic liver disease, with a special
emphasis on the therapeutic implications.
Pathophysiological and molecular features of
95 hepatic insulin resistance
Insulin is involved in mediating the metabolic transition
that happens upon refeeding through tight regulation of
several pathways. Insulin action is required for maintain-
ing the balance between nutrients intake and storage. In
100 fact, insulin promotes energy storage in adipose tissue,
liver andmuscle by stimulating lipogenesis, glycogen and
protein synthesis and inhibiting lipolysis, glycogenolysis
and protein breakdown,[12] and regulates food intake
and behavior. MetS and NAFLD are characterized by IR,
105 so that higher levels of insulin are required to counteract
hyperglycemia and maintain glucose homeostasis. The
pancreatic β-cells compensate the impaired insulin
response by increasing insulin production, but eventually
in susceptible individuals, β-cells undergo exhaustion,
110 and glucose concentration in the blood rises, leading to
impaired glucose tolerance and T2DM.
From a clinical point of view, individuals are generally
defined as insulin resistant by their response to an oral or
intra venous glucose or insulin challenge.[13] Hyper-insu-
115 linemic euglycemic clamp techniques represent the gold
standard for IR quantification. During the hyper-insuline-
mic euglycemic clamp, insulin  -resistant subjects show
reduced capability to metabolize glucose due to lower
peripheral glucose clearance and unblunted hepatic glu-
120 cose production. The oral glucose tolerance test  is
commonly performed in clinical practice to classify
patients according to their glycemic status (normal,
impaired glucose tolerant  or diabetic). IR can also be
estimated from biochemical parameters using several
125indices. First described in 1985, the homeostasis model
assessment-insulin resistance (HOMA-IR) is the most
widely used index for the clinical assessment of IR.
IR may be caused directly from altered insulin recep-
tor (INSR) activity, or by alterations in the downstream
130signaling pathways. The former is rarely determined by
loss-of-function mutations of INSR gene, but most fre-
quently reflects reduced expression on the cellular
membrane. This is particularly relevant in the liver dur-
ing NAFLD, and is involved in the pathogenesis of
135hyperinsulinemia by decreasing insulin clearance.[14]
Genetic and acquired alterations in insulin signaling
play a major role in tissue specific IR. Under physiological
conditions, insulin binding to INSR on the plasma mem-
brane leads to INSR auto-phosphorylation and the conse-
140quent tyrosine phosphorylation of insulin receptor
substrates-1 and -2 (IRS1 and IRS2). This event starts a
signaling cascade resulting in phosphatidylinositol 3-
kinase (PI3K)  -mediated AKT activation. In hepatocytes,
AKT induces phosphorylation of Forkhead transcription
145factor O1 (FOXO1), favoring translocation out of the
nucleus and the shut  down of transcription of target
genes. Among FOXO1-regulated genes, glucose-6-phos-
phatases (G6Pc), the rate-limiting enzyme in gluconeo-
genesis and hepatic glucose release,[15] plays a key role.
150On the other hand, insulin induces sterol regulatory
element-binding protein-1c (SREBP1c), which enhances
transcription of genes required for de novo lipogenesis:
Acetyl coenzyme A carboxylase  and fatty acid synthase
(FAS).[16] As de novo lipogenesis proceeds, the inter-
155mediate malonyl coenzyme A accumulates in the cyto-
sol and inhibits carnitine palmitoyltransferase-1  , the
transporter that shuttles fatty acids into the mitochon-
dria and the rate-limiting enzyme of fatty acids β-oxida-
tion. Newly synthesized   TGs  are then packaged with
160apolipoprotein B  into very low-density lipoproteins
(VLDL) and exported for peripheral use.
In peripheral metabolic tissues, muscle and fat, insu-
lin stimulates dietary glucose uptake by driving the
translocation of glucose transporter GLUT4 to the cell
165surface and promotes fat storage through induction of
lipoprotein lipase, which in turns hydrolyzes circulating
TG to fatty acids that, once inside the cells, can be re-
esterified by adipocytes or oxidized for energy by myo-
cytes. At the same time, in order to prevent release of
170stored fatty acids back to circulation, insulin inhibits
lipolysis and induces lipogenesis in adipocytes.
Individuals affected by obesity and T2DM show sig-
nificant decrease of IRS1-associated tyrosine
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phosphorylation and PI3K activity in skeletal muscle
175 and adipose tissue. Subjects with T2DM show also
reduced INSR expression and activity in both muscle
and adipocytes. During NAFLD, IR prevents AKT  -
mediated inactivation of FOXO1 and its downstream
targets,[17,18] resulting in deregulation of gluconeo-
180 genesis and persistent hepatic glucose output that
cause mild hyperglycemia and hyperinsulinemia.
Furthermore, oxidative stress associated with NASH
induces FOXO1 de-acetylation mediated by SIRT1,
resulting in unrestricted hepatic glucose output inde-
185 pendently of FOXO1 phosphorylation status, despite
improved adipose tissue insulin sensitivity.[19,20]
However, it should be noted that overall evidence sug-
gests in muscle, adipose tissue  and at whole body level,
SIRT1 activation improves insulin sensitivity.[20,21]
190 As previously anticipated, MetS and NAFLD are char-
acterized by “selective” or “dissociated” hepatic IR. In fact,
insulin maintains the ability to induce de novo lipogenesis
by increasing SREBP1c and preventing β-oxidation.
NAFLD patients have 2-fold higher de novo lipogenesis
195 compared to subjects with low liver fat concentration.[22]
Several hypotheses have been raised to explain this
apparent conundrum; here we will discuss some. Insulin
signaling through different isoforms of IRS and AKT may
contribute explaining dissociated hepatic IR during MetS.
200 Specifically IRS2 and AKT2 would be involved in de novo
lipogenesis,[23,24] and FOXO1 may represent the mole-
cular switch of selective hepatic IR. Indeed, FOXO1
becomes active in the presence of IR and NAFLD, but it
induces IRS2 and down  regulates inhibitors of AKT.[25,26]
205 Furthermore, unrestricted FOXO1 activation contributes
to dyslipidemia by reducing VLDL secretion, by down  re-
gulating MTTP  and by inducing APOC3, a circulating inhi-
bitor of lipoprotein lipase. Conversely, FOXO1 silencing by
antisense oligonucleotides improved steatosis,  IR  and dys-
210 lipidemia in experimental models.[27]
Notably, increased AKT2 activity has been also impli-
cated in the progression of NAFLD to HCC. Indeed, liver-
specific deletion of the AKT inhibitor PTEN results in
severe steatosis evolving to HCC, and PTEN is frequently
215 mutated during hepatic carcinogenesis.[28]
Recently, NOTCHAQ2   -dependent signaling has been shown
to play an important role in hepatic lipid metabolism reg-
ulation by interfering with insulin signaling. NOTCH recep-
tor engagement mediates cell-fate decisions via
220 interactions among neighboring cells and is involved in
liver development and repairing. Recent studies have
revealed a pivotal role of NOTCH in gluconeogenesis and
lipogenesis regulation. An aberrant activation of this path-
way in hepatocytes leads to hyperglycemia and fatty acids
225 accumulation.[29,30] NOTCH regulates glucose and lipid
homeostasis mainly through synergy with FOXO1 and
AKT. In mouse models, combined haplo-insufficiency for
Foxo1 and Notch-1 ameliorated insulin sensitivity in diet-
induced IR.[30] Indeed, pharmacological blockade of Notch
230signaling by γ-secretase inhibitors improved glucose toler-
ance and IR. Conversely, constitutive activation of Notch-1
in liver induced G6Pc expression, exacerbating IR in a
FOXO1-dependent manner. Remarkably, NOTCH signaling
uncouples gluconeogenesis activation and lipogenesis
235suppression. Liver-specific constitutive activation of Notch
leads to steatosis, stabilizing mammalian target of rapamy-
cin complex 1 (mTORC1) and stimulating SREBP1c-induced
lipogenesis. Conversely, Notch ablation prevented steatosis
blocking mTORC1 activity. Notably, NOTCH signaling acti-
240vation is also observed in patients with NAFLD, and is
correlated with the severity of IR and liver damage, sug-
gesting that it may be involved in NASH pathogenesis.[31]
Furthermore, Notch pathway activationmay be involved in
the process of fibrogenesis by promoting ductular reaction
245and neovessel proliferation.[32]
A schematic representation of the main alterations in
hepatic insulin signaling discussed in this review is pre-
sented in Figure 1.
Another pathway deregulated during MetS is repre-
250sented by bile acids signaling. Bile acids are increasingly
recognized as key regulators of systemic metabolism.
Bile acid interactions with the nuclear hormone recep-
tor farnesoid X receptor (FXR) and the membrane
receptor G-protein-coupled bile acid receptor 5  regu-
255lates the secretion of incretins and fibroblast growth
factor 19  , lipid metabolism, and energy expenditure,
contrasting IR development. Bile acid levels and distri-
bution are altered in T2DM and increased following
bariatric procedures, and the bile acid metabolome is
260also altered in NASH.[33] Thus, modulation of bile acid
levels and signaling may be exploited to treat IR and
related liver disease.[34] Interestingly, recent studies
indicate that the alterations in the bile acid pool during
fatty liver and IR may be related to altered hepatic
265insulin signaling via unrestricted activation of FOXO1.
[35,36]
Insulin resistance in liver diseases
development: NAFLD
Epidemiological data from cross-sectional studies indicate
270that IR, MetS  and T2DM are associated with liver damage
severity and fibrosis,[37] independently of liver enzymes.
[38] Previously, it was believed that NAFLD progresses to
advance liver disease only in the presence of inflamma-
tion. However, a recent meta-analysis of prospective stu-
275dies a new data AQ3from a large cohort provided novel results
indicating that T2DM is associated with more rapid pro-
gression of fibrosis, even in the absence of NASH.[10,11]
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Underscoring the relevance of these findingsAQ4 , recent data
indicate that the severity of fibrosis, and not the presence
280 of NASH  , in the major determinant of NAFLD prognosis.
[39,40]
Although the exact mechanism of progressive liver
disease in NAFLD is still under definition, current knowl-
edge supports a model whereby development of liver
285 damage is multifactorial, commonly summarized as the
  multi-hits  hypothesis.[41] The  first hit  causes hepatic fat
accumulation due to IR. Initially, hepatic fat accumula-
tion results from an increased efflux of non-esterified or
free fatty acids (FFA) from the adipose tissue to the
290 liver.[42] FFA are stored into the hepatocytes as TG, in
order to protect hepatocytes themselves from lipotoxi-
city.[42] Reduction in neutral lipid secretion through
VLDL [43] and in β-oxidation due to mitochondrial
damage are also involved in hepatic fat accumulation.
295 Excess of intracellular accumulation of lipid metabo-
lites, such as diacylglycerol, ceramides and long chain
acyl CoA, has also been implicated as a mediator of IR.
[44,45] Aberrant accumulation of these bioactive inter-
mediates engages c-Jun-N terminal kinase (JNK) that
300 contributes to IR by phosphorylating IRS1 at serine
residues, inhibiting its activity.[46] Indeed, accumula-
tion of ceramides and/or diacyl-glycerol triggers the
activation of atypical protein kinase C (PKC) isoforms
that phosphorylate JNK.[47,48] Furthermore, in NASH
305patients, activation of the JNK pathway, which is
involved in induction of programmed cell death by
triggering mitochondrial damage in response to inflam-
mation and/or cellular stress, may also contribute
directly with the progression of liver damage, as it
310correlates with hepatocellular death by apoptosis.[49]
Visceral obesity also contributes to NASH develop-
ment. Several adipokines are released by adipose tissue,
such as adiponectin, leptin, resistin, TNF-α, IL-1β  and IL-
6. These adipokines down  regulate the expression of the
315glucose transporter GLUT-4 expression via increased
serine IRS1 phosphorylation,[12] inducing IR.[50]
In addition, genetic experiments in mouse models
suggest that hepatic IR directly contributed to the pro-
gression of liver damage. This has been shown in liver-
320specific INSR knockout mice  , which display severe pri-
mary IR and a defect in insulin clearance. These mice
develop an age-dependent nodular hyperplasia of the
liver, oxidative stress and liver dysfunction with
impaired ability to regenerate following partial hepa-
325tectomy. Moreover, IRS2-deficient hepatocytes are more
susceptible to apoptosis.[51] This evidence suggests a
causal role of IR in liver disease progression.
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Figure 1. The insulin signaling pathway in hepatocytes. Insulin (I) binding to its receptor (INSR) leads to auto-phosphorylation of INSR,
resulting in phosphorylation of the insulin-receptor substrates (IRS1 and IRS2), activation of phosphoinositide 3-kinase (PI3-kinase)
and subsequent phosphorylation of AKT 1/2. Activation of protein kinase AKT1/2 mediates the metabolic effect of insulin
inactivating the transcription factor FOXO1, which  in the absence of insulin induces gluconeogenesis, lipoprotein export  and
apoptosis. Phosphorylation of FOXO1 in response to insulin leads to its nuclear exclusion, ubiquitination  and subsequent
proteasomal degradation. NOTCH1 regulates gluconeogenesis through synergy with FOXO1 and lipid homeostasis by enhancing
AKT activation of mammalian target of rapamycin (mTORC1), which contributes to induction of de novo lipogenesis through
SREBP1c.
4 P. DONGIOVANNI ET AL.
Human genetics seems to confirm that IR determines
hepatocellular damage and fibrosis progression in
330 NAFLD.[52] Functional common genetic variants of
molecules involved in insulin signaling, such as IRS1
and ectonucleotide pyrophosphatase/phosphodiester-
ase1 (ENPP1 or PC-1) have been associated with the
severity of liver damage.[53] Moreover, loss or gain-of-
335 function mutations in these genes increase the risk of IR
and T2DM, respectively. Thus, the amelioration of IR
might improve the long-term outcomes of NAFLD
patients. Since genetic variants are independent of con-
founders and reverse causation is not an issue, genetic
340 data indicating that loss-of-function variants in the insu-
lin signaling pathways are associated with more severe
fibrosis suggest that IR has a causal role in NAFLD
progression. This does not rule out that progressive
NAFLD may be triggered by other insults in patients
345 and in animal models. Indeed, the most studied mouse
model of fibrosing NAFLD is induced by methionine-
and choline  -deficient  diet, where altered hepatic lipid
metabolism is deranged by nutritional deficiencies
instead of IR.[42]
350 During the last years, genome-wide association stu-
dies have revealed that polymorphisms in genes
involved in TG remodeling and VLDL secretion play a
major role in steatosis and NASH development and liver
damage progression, though they have no impact on
355 IR. These data suggest that IR is more a cause of stea-
tosis and progressive liver disease than a consequence
of these processes.[37,54,55] The mechanism may
involve alteration of hepatic lipid metabolism favoring
lipotoxicity or a direct effect on hepatocellular regen-
360 eration and the regulation of fibrogenesis.
Mechanisms of progressive liver injury
associated with IR
The mechanisms underpinning liver damage progres-
sion related to IR have been investigated during last
365 years. Excess hepatic FFA results in the generation of
toxic lipid metabolites, which cannot be safely dis-
posed of via mitochondrial β-oxidation, but are
shifted toward  peroxisomal and microsomal oxidation.
These pathways produce more reactive oxygen spe-
370 cies (ROS), worsening oxidative stress. Lipotoxicity, i.e.
cellular injury and death caused by FFA and their
metabolites, represents the major mechanism under-
lying hepatocellular dysfunction leading to the devel-
opment of hepatitis. Lipotoxicity induces   alteration in
375 cellular metabolism leading to organelles injuries;
  oxidative stress;   activation of stress  -related signaling
pathways, such as atypical PKC isoforms and JNK; and 
elevated pro-inflammatory cytokines and activation of
Kupffer cells, which requires engagement of Toll-like
380receptor-4 (TLR-4) by intestinal bacterial products
entering the portal circulation due to altered intest-
inal microbiota and increased permeability,[56] and
directly by oxidized lipid species.[57] In parallel,
  excess free cholesterol trafficking to mitochondria
385leads to glutathione depletion impairing cellular anti-
oxidant machinery and inducing hepatocellular sus-
ceptibility to TNFα and FAS.[58]
Lipotoxic injury induces mitochondrial dysfunction
and endoplasmic reticulum stress, playing a central
390role in fat accumulation and ROS generation.
Consequently, several self-sustained vicious cycles
involving lipid peroxidation, mitochondrial DNA
damage, ROS formation, depletion of antioxidants and
cytokine release may trigger necroinflammation and
395fibrogenesis. Indeed, NASH patients had functional
and morphological abnormalities in mitochondria,[59]
impaired ability to re-synthesize ATP after carbohydrate
challenge, and decreased respiratory chain complex
activity.[60]
400ROS accumulation can also cause endoplasmic reti-
culum stress and the consequent activation of the
compensatory unfolded protein response pathway.
Endoplasmic reticulum stress increases the activity of
JNK and IKK (inhibitor of nuclear factor-κB – NF-κB –
405kinase), further impairing insulin signaling [46] and
leading to activation of CREB-H AQ5, a transcription regulat-
ing inflammatory and acute-phase responses in the
liver.[61]
The progression of liver damage is marked by accu-
410mulation of hepatic fibrosis resulting from deposition of
extra-cellular matrix (ECM) by hepatic stellate cells
(HSC). HSC are usually quiescent and reside in the
sinusoids adjacent to hepatocytes. Once activated by
injury, HSC loose retinoids contained in lipid droplets,
415proliferate and migrate to the sites of tissue damage,
assuming a matrix-producing, contractile phenotype, as
well as the ability to produce cytokines and chemokines
that perpetuate inflammation and fibrogenesis. The
ability of activated HSC to secrete collagen and other
420components of the ECM is potently stimulated by tissue
growth factor-beta  , as well as by lipid peroxidation
products and connective tissue growth factor (CTGF).
[62] In particular, hyperinsulinemia and hyperglycemia
stimulate HSC to produce ECM, fibrosis deposition and
425  CTGF secretion. Interestingly, it has recently been
shown that the PNPLA3 I148M variant, the major
genetic risk factor for NAFLD/NASH, alters retinol
release by HSC, potentially contributing directly to
fibrogenesis and carcinogenesis.[55,63]
430Following resolution of damage, most activated HSC
undergo apoptosis. Senescence of persistent HSC in
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response to chronic inflammation is now thought to con-
tribute to the pathogenesis of HCC in NASH. In  animal
models of NASH, alterations of intestinal gut microbiota
435 result in TLR-4 activation in Kupffer cells, triggering inflam-
mation and  contributing to the onset of senescence-asso-
ciated secretory phenotype  in HSC.[64] Interestingly,
epidemiological and pathological evidence indicate that
HCC in NAFLD frequently occurs outside cirrhosis.[65]
440 Potential mediators of carcinogenesis include genetic fac-
tors and IR-mediated lipotoxicity, de  regulation of proin-
flammatory/anti-inflammatory cytokines,
hyperinsulinemia and deregulation of the insulin signaling
pathway, which  provide a permissive microenvironment
445 for the development of cancer. However, the relative role
of such pathways and their interplay with individual
genetic background remain to be investigated.[66] The
main mechanisms involved in liver damage progression
related to IR are shown in Figure 2.
Impact of insulin sensitizers on liver disease
450progression
Since IR is a key driver of liver disease progression,
insulin-sensitizing drugs are currently undergoing
extensive evaluation with regard to safety and ability
to improve hepatic inflammation and fibrogenesis,
455while at the same time reducing the metabolic altera-
tions that occur  because of fatty liver. Until recently, the
two most widely used classes of molecules are repre-
sented by metformin and thiazolidinediones (TZD).
Metformin is an AMPK AQ6-activating biguanide that
460represents the cornerstone of T2DM treatment.[67] It
improves IR decreasing hepatic gluconeogenesis; 
enhances fatty acid oxidation, peripheral and hepatic
insulin sensitivity  ; and induces weight loss. It decreases
also intestinal glucose absorption, facilitating skeletal
465muscle glucose uptake. Steatosis, inflammation and
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Figure 2. Schematic cartoon depicting the pathophysiological role of insulin resistance in the development and progression of liver disease. Multiple
parallel hits, including insulin resistance (IR), genetic factors, intestinal microbiota and inflammation account for steatosis devel-
opment and progression. Fatty liver is characterized by  FFA  accumulation in lipid droplets resulting from an unbalance between
triglycerides acquisition and removal. FFA stored as triglycerides during hepatic steatosis derive from peripheral lipolysis related to
adipose tissue IR, followed by de novo lipogenesis (DNL) induced by hyperinsulinemia, and excessive food intake. FFA can be
catabolized through β-oxidation and re-esterification to TG and stored as lipid droplets or exported as  VLDL  . Impaired ability to
secrete VLDL and decreased β-oxidation due to mitochondrial damage play a role in hepatic fat accumulation. Long-term injury
arising from  TG storage and lipotoxicity;  (ii) oxidative stress secondary to free radical produced during FFA oxidation;  inflammation
triggered by endotoxin  ;   cytokine  release;   and endoplasmic reticulum (ER) stress lead in the end to inflammation (NASH),
perpetuation of cellular damage  and activation of fibrogenesis. Direct recruitment of Kupffer cells (KC) and other components of
the innate immune response occurs with activation of the inflammation and the coordinated release of pro-inflammatory and
fibrogenic cytokines. Hepatic stellate cells (HSC) are subsequently activated to produce extra-cellular matrix (ECM) leading to
progressive fibrosis, cirrhosis and its complications (e.g., hepatocellular carcinoma  (HCC)). Apoptotic bodies and factors produced by
senescent cells (senescence-associated secretory phenotype  (SASP)) can also influence HSC activity.
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fibrosis were improved in NASH patients treated with
metformin (2 g/day) for 12 months. Specifically, metfor-
min reduced aminotransferase levels and hepatic
expression of TNF-α, which interferes with insulin sig-
470 naling in hepatocytes. However, subsequent studies
and a meta-analysis showed that metformin was not
an effective treatment for patients with NASH without
T2DM, as it was not superior to placebo for any histo-
logical or biochemical outcome. The main randomized
475 controlled studies are reported in Table 1.[68] However,
in non-randomized retrospective clinical studies, met-
formin has been associated with reduced incidence of
HCC and mortality in cirrhosis, although the mechanism
is not clear. Notably, metformin reduced by about 50%
480 HCC risk even in hepatitis C virus (HCV)-infected
patients. Nonetheless, metformin should be used with
caution in patients with decompensated cirrhosis, as it
can accumulate during liver and renal failure and cause
lactic acidosis.
485 TZD are peroxisome active proliferator receptor
(PPAR)γ agonists, which promote hepatic fatty acid oxi-
dation, decrease hepatic lipogenesis and improve insu-
lin sensitivity. PPARγ is a nuclear hormone receptor,
acting as transcription factor that controls adipocyte
490 differentiation and the production of adiponectin.
Indeed, TZD stimulate FFA storage in subcutaneous
adipocytes.[81] TZD include different compounds, such
as pioglitazone and rosiglitazone, even if the use of
rosiglitazone has been limited as a result of increased
495 cardiovascular risk due to fluid retention. TZD amelio-
rate insulin sensitivity, steatosis, adiponectin and ami-
notransferases in NAFLD. The effects on inflammation
and fibrosis are variable. However, anti-inflammatory
properties may be suggested by a decrease in NF-κB
500 expression and by an increase in IκB and adiponectin
levels. In multiple small pilot studies, daily administra-
tion of rosiglitazone (8 mg/day for 12 months) and
pioglitazone (30 mg/day) improved insulin sensitivity,
aminotransferases and liver damage in obese patients
505 with biopsy-proven NASH without T2DM and cirrhosis
(Table 1). A recent meta-analysis indicated that high  -
quality evidence supports the effects of TZD in improv-
ing ballooning degeneration and possibly inflamma-
tion, but not fibrosis.[82] Furthermore, the beneficial
510 effects of these drugs disappear after treatment inter-
ruption suggesting that they should be administrated
to patients life-long. In addition, the clinical use of TZD
is limited by the occurrence of several adverse effects
including weight gain, increased risk of congestive
515 heart failure, osteoporosis  and bladder cancer.[83]
The effects of PPARγ agonists on NAFLD may be
explained by the ability to target different tissues and
pathways. First, PPARγ activation improves IR in
peripheral tissues, thus decreasing FFA flux to the
520liver. Second, PPARγ inhibits activation and proliferation
of HSC, thus preventing fibrogenesis. Third, PPAR dis-
plays anti-inflammatory effects in macrophages and in
hepatic endothelial cells.[84] Therefore, manipulation of
nuclear receptors by potent specific ligands may repre-
525sent a viable approach to prevent the development and
progression of liver disease related to IR.[84]
Bile acid receptors, including FXR, have more
recently been implicated in the regulation of hepatic
IR and lipid metabolism.[34] In a randomized trial, the
530FXR agonist obeticholic acid (OCA) improved the bio-
chemical and histological features of NASH in patients
without T2DM and cirrhosis.[85] However, improvement
in fibrosis was mild, and the drugs determined an
increase in serum cholesterol despite concurrent treat-
535ment with statins, raising concern on the possible car-
diovascular risk profile with long-term treatment.
Interestingly, amelioration of liver damage in OCA-trea-
ted patients occurred in spite of a mild increase in the
HOMA-IR index, suggesting that the beneficial effect
540was independent of  IR.
Lastly, clinical studies are ongoing to evaluate the
impact of PPARα/δ ligands on hepatic damage in
patients with NASH, as these molecules improved IR
and lipid metabolism in preclinical models of MetS
545and steatohepatitis.[86]
Clearly, further studies are required and several are
already ongoing, but modulation of nuclear hormone
receptors activity represents a promising approach,
possibly to be used in combined regimens for preven-
550tion of liver disease progression.
Insulin resistance in the progression of other
liver diseases
The role of IR in determining the progression of liver
disease is not restricted to “pure” NAFLD. HCV infection
555affects 1–3% of the world population and is a major
cause of chronic liver disease and cirrhosis.[87] HCV
directly alters glucose homeostasis and is associated
with an increased risk of IR and T2DM, especially in
patients at risk due to obesity and aging.[88] IR occurs
560in early stages of hepatic lesions and it worsens as
hepatic fibrosis progresses,[89] but viral eradication
decreases IR.[90] Several hypotheses have been pro-
posed to explain HCV induction of IR:   inflammatory
cytokines, such as TNF-α and IL-6, that induce IR
565through tyrosine phosphorylation of IRS1;   induction of
suppressor of cytokines signaling (SOCS3), which pro-
motes proteasomal degradation of IRS1/2  ; and
  increased oxidative stress and lipid peroxidation, trig-
gering inflammation and IR.[91]
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570 The severity of IR has been associated with fibrosis
progression also in chronic HCV hepatitis.[89] Indeed,
serum insulin and HOMA-IR are higher in HCV patients
compared to uninfected controls and increase with
fibrosis development.[89,92] Thus, IR is a driving force
575 that promotes disease progression in patients infected
with HCV.[93] On the other hand, steatosis also accel-
erates fibrogenesis in chronic HCV hepatitis.[94] In addi-
tion, steatosis and IR were associated with lower
response rate to interferon based-therapy.[95] The use
580 of insulin sensitizer drugs (TZD or metformin) has there-
fore been tested with variable success to increase the
efficacy of these treatments (the main studies are
reported in Table 2). However, the clinical relevance of
these findings is vanishing in the new direct antiviral
585 agents  era.
The frequency of steatosis and T2DM is lower in
patients with chronic hepatitis B (HBV)AQ10 than in HCV-
infected patients. Although the incidence of HBV infec-
tion has decreased since the implementation of hepa-
590 titis B vaccination, HBV still represents an important
health problem worldwide, and MetS increases liver
fibrosis progression and HCC incidence even in this
setting.[102,103] IR is also a major risk factor for the
progression of alcoholic liver disease (ALD). ALD is a
595 complex disease whose development depends on long-
term excessive drinking and other environmental,
acquired and inherited factors. It is the major cause of
liver failure worldwide. The histological spectrum of
ALD includes simple steatosis, steatohepatitis and cir-
600 rhosis. However, the majority of individuals who abuse
alcohol do not develop cirrhosis.
Importantly, increased adiposity and fasting glucose are
independently associated with disease severity in ALD.
Conversely, ALD patients have high basal levels of insulin
605and an impaired insulin signaling. Impaired insulin secre-
tion, tissue response to insulin, non-oxidative glucose dis-
posal and glucagon response may contribute to IR in ALD.
The mechanism through which alcohol interferes with
insulin signaling is not well understood. Both in vitro and
610in vivo studies reported an interference of alcohol on insu-
lin signaling, through several mechanisms:  direct binding
of alcohol to INSR,  inhibition of INSR phosphorylation or
internalization, and  impairment of downstream insulin sig-
naling. Taken together, these alterations lead to disease
615progression, increasing the risk of advanced disease.
However, due to the difficulty to conduct studies in this
setting, to date there are no data supporting the clinical
use of insulin sensitizers in ALD.[104]
Finally, large epidemiological studies indicate that obe-
620sity is associated with higher risk of HCC.[66] Moreover,
obesity is an independent predictor of HCC in patients
with alcoholic and cryptogenic cirrhosis.[66] Several popu-
lation studies indicate that T2DM is also a risk factor for
HCC.[105] It has been hypothesized that a high concentra-
625tion of insulin and insulin growth factor 1  in T2DM may
have carcinogenic activity.[106] This would suggest that
glucose  -lowering drugs, such as metformin, could reduce
HCC development in at risk patients.[107]
Conclusions
630IR represents the most frequent trigger of NAFLD.
Initially, hepatic fat accumulation results from an
increased flux of non-esterified or FFA to the liver due
to adipose tissue IR. Nonetheless, hyperinsulinemia and
diet activate lipogenic transcription factors and induce
635de novo lipogenesis. Furthermore, fatty liver per se
Table 2. Impact of antiviral therapy combined with insulin sensitizing drugs on virologic response and insulin sensitivity in HCV
patients.
Authors
Study
type
Subjects
enrolled
HCV
genotypes Therapy (dose per day)
Compared with
(dose per day)
Duration
(weeks) Outcomes
Virologic response
OR (95% CI)
Insulin
sensitivity
Overbeck
[96]
RCT 5 Mixed Piogl(15 mg) + PegIFN/rib Baseline 12 Not improved Improved
Khattab [97] RCT 97 4 Piogl (30 mg) + PegIFN/rib PegIFN/rib 12 Improved
2.81 (1.15–6.85)
Improved
Chojkier
[98]
RCT 20 4 Piogl (30 mg) + PegIFN/rib Baseline 2 Not assessed Improved
Harrison
[99]
OL,
RCT
77 1 Piogl
(30–45 mg) + PegIFN/rib
PegIFN/rib 48 Not improved
0.56 (0.28–1.12)
Improved
Romero-
Gomez
[100]
RCT 123 1 Met (1275 mg weeks 1–4/2550 mg
weeks 4–48) + PegIFN/rib
Placebo + PegIFN/
rib
48 Not improved
1.51 (0.74–3.09)
Improved
Sharifi [101] RCT 140 Mixed Met (1500 mg) + PegIFN/rib Placebo + PegIFN/
rib
24/48
According
genotypesAQ9
Not improved
0.42 (0.19–0.90)
Not
improved
Met: metformin; OL: open label;  PegIFN: pegylated interferon; Piogl: pioglitazone; RCT: randomized controlled trial; Rib: ribavirin.
References are reported in the Supplementary material.
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precipitates hepatic IR promoting metabolic distur-
bances and cardiovascular damage. IR may be caused
directly from altered INSR activity (loss-of-function
mutation or reduce cell membrane expression), or by
640 alterations in the downstream signaling pathways. In
the presence of impaired insulin signaling the transcrip-
tion factor FOXO1 is de-phosphorylated, determining
unrestrained transcription of genes involved in glucose
production. Recently, NOTCH signaling has been impli-
645 cated in the upregulation of G6Pc expression in a
FOXO1-dependent manner during IR, while at the
same time stimulating de novo lipogenesis. Thus, IR
promotes NASH development and liver damage pro-
gression. Hepatic lipotoxicity, oxidative stress, inflam-
650 mation and cytokines release are important
contributing factors. Genetic studies suggest that IR
has a causal role in disease progression.
Insulin sensitizing drugs are currently evaluated with
regard to safety and ability to improve histological
655 features and inflammation. Recent meta-analyses
showed that metformin is an ineffective treatment for
patients with NASH without T2DM, whereas TZD are
effective in improving ballooning degeneration and
possibly inflammation, but not fibrosis, and are bur-
660 dened by side effects. A novel approach to treat IR
and steatosis development is represented by manipula-
tion of nuclear receptors, which control glucose and
lipid metabolism, inflammation  and fibrogenesis, by
potent specific ligands. Nevertheless, further research
665 is warranted to better understand the mechanism link-
ing IR and chronic liver diseases and to identify new
therapeutic targets.
Expert commentary
During recent years, the field of IR in liver disease has
670 witnessed important novelties at different levels,  from
both the pathophysiological and therapeutic point of
view.
At the basic research level, the mechanisms underpin-
ning dissociation of hepatic IR during metabolic diseases,
675 i.e.  lack of suppression of glucose production by insulin
despite heightened drive on lipogenesis, have begun to be
unraveled. Indeed, activation of bile acid receptors, as well
as of other pathways that converge on FOXO1 and mTOR,
in particular the NOTCH pathway, have been shown to
680 modify insulin action promoting hepatic fat accumulation
and dyslipidemia. These findings have major implication
for understanding both the liver-related complications of
nonalcoholic fatty liver disease and cardiovascular disease
in strongly associated MetS  . Furthermore, they provide
685 attractive new therapeutic targets.
Indeed, accumulating evidence from clinical studies
has dampened the hope that currently used insulin
sensitizing drugs have major beneficial effects on liver
disease progression. Though it may reduce mortality in
690cirrhosis, metformin did not ameliorate steatohepatitis
and fibrosis in individuals without T2DM. On the other
hand, pioglitazone improved steatosis with possible
minor effect on fibrogenesis, but is burdened by severe
side effects. However, great expectations stem from the
695clinical development of new classes of drugs, which
may also regulate  IR, such as PPARα/δ and FXR agonists.
The first trial in NASH  showed that the prototypical
compound OCA reduced liver damage, despite an
increase in serum cholesterol.
700Future studies are still required to understand the
mechanisms by which   IR determines progression of
liver disease, as new evidence points out that the effect
may be independent of inflammation, and to develop
the aforementioned novel therapeutic approaches.
705Five-year view
In the next five years, we expect that at the basic
research level, the detailed molecular mechanisms of
dissociated hepatic IR during steatosis will be clarified.
In particular, the sources and regulation of NOTCH
710signaling identified, as long as novel therapeutic targets
in this pathway.
Furthermore, the impact of IR on liver fibrosis pro-
gression will be widely recognized as independent by
inflammation, and the cellular mechanisms character-
715ized. This will have a major impact for the clinical
management, indication for therapy, and the design
and inclusion criteria for clinical trials in metabolic
liver diseases. Besides, it will provide a new approach
to therapy.
720Concerning the ongoing clinical studies, the efficacy
of FXR and PPAR α/δ ligands will be clarified. FXR
ligands will likely be developed in combinations with
statins and possibly anti-fibrotic agents, and the first
drug regimens will hopefully be approved by regulatory
725agencies for the treatment of NASH.
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